0001553878-18-000023.txt : 20180314 0001553878-18-000023.hdr.sgml : 20180314 20180314194023 ACCESSION NUMBER: 0001553878-18-000023 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180312 FILED AS OF DATE: 20180314 DATE AS OF CHANGE: 20180314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KEATING LAURIE CENTRAL INDEX KEY: 0001620743 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36407 FILM NUMBER: 18690708 MAIL ADDRESS: STREET 1: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001178670 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770602661 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 551-8200 MAIL ADDRESS: STREET 1: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020724 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2018-03-12 0 0001178670 ALNYLAM PHARMACEUTICALS, INC. ALNY 0001620743 KEATING LAURIE 300 THIRD STREET CAMBRIDGE MA 02142 0 1 0 0 SVP, GC & Secretary Common Stock 2018-03-12 4 M 0 10000 77.4 A 24500 D Common Stock 2018-03-12 4 S 0 10000 140.0 D 14500 D Common Stock 2018-03-13 4 M 0 10000 77.4 A 24500 D Common Stock 2018-03-13 4 S 0 10000 150.0 D 14500 D Common Stock 257 I by Managed Account Stock Option (right to buy) 77.4 2018-03-12 4 M 0 10000 0.0 D 2024-09-22 Common Stock 10000 82000 D Stock Option (right to buy) 77.4 2018-03-13 4 M 0 10000 0.0 D 2024-09-22 Common Stock 10000 72000 D All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. The reporting person owns 257 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. By: /s/ Michael P. Mason, Attorney-in-Fact For: Laurie Keating 2018-03-14